Overall survival in patients over 40 years old with surgically resected pancreatic carcinoma: a SEER-based nomogram analysis

Jian Li* and Leshan Liu

Abstract

Background: The aim of this study was to identify the determinants of overall survival (OS) within patients over 40 years old with surgically resected pancreatic carcinoma (PC), and to develop a nomogram with the intention of OS predicting.

Methods: A total of 6341 patients of 40 years of age or later with surgically resected PC between 2010 and 2015 were enrolled from the Surveillance, Epidemiology, and End Results (SEER) program and randomly assigned into training set (4242 cases) and validation set (2099 cases). A nomogram was constructed for predicting 1-, 2- and 3-years OS based on univariate and multivariate Cox regression. The C-index and calibration plot were adopted to assess the nomogram performance.

Results: Our analysis showed that age, location of carcinoma in pancreas, tumor grade, TNM stage, size of carcinoma together with lymph node ratio (LNR) were considered to be independent overall survival predictors. A nomogram based on these six factors was developed with C-index being 0.680 (95%CI: 0.667–0.693). All calibration curves of OS fitted well. The OS curves stratified by nomogram-predicted probability score (≥20, 10–19 and < 10) demonstrated statistically significant difference not only within training set but also in validation set.

Conclusions: The present nomogram for OS predicting can serve as the efficacious survival-predicting model and assist in accurate decision-making for patients over 40 years old with surgically resected PC.

Keywords: Pancreatic carcinoma, Prognosis, Overall survival, Nomogram

Background

Pancreatic carcinoma (PC), an extraordinarily common cancer, ranks as the fourth leading cause of cancer death in the western countries [1]. The morbidity and mortality of PC have been on the rise currently, and its morbidity shows a youth oriented tendency. Most of PC patients are older than 40 years of age. Worldwide, PC accounts for more than 200,000 deaths annually. Moreover, it is anticipated to become the second dominating death cause in malignant neoplasms by 2030 [2]. In spite of great progresses in surgery, neoadjuvant chemoradiotherapy and immunotherapy, PC prognosis still remains dismal with the overall survival (OS) of 5-year hovering at 8% [3]. The potentially curative therapy for PC patient is surgical resection. Nevertheless, merely 20% of PC patients are potentially curative resected candidates owing to difficulty in early diagnosis [4], and the prognosis of long-term is poor [5]. Among patients undergoing radical resection, recurrence will occur in most patients ultimately. Hence, clinicopathologic-based, personalized prognostic evaluation of PC patients can be in favor of undertaking superior therapeutic strategies.

Since PC is heterogeneous with respect to survival of individual patients, it is necessitated to develop a more personalized prognostic tool which may offer the precise survival prediction for these patients. Presently, the staging system of Tumor-Node-Metastasis (TNM) derived...
from the 8th edition of American Joint Commission on Cancer (AJCC), formulated for prognostic predicting after surgical resection, is one of the most widely adopted predictor of cancer prognosis [6, 7]. The TNM classification system only takes carcinoma size and extent, presence of lymph nodes metastasis and distant recurrence into account. Actually, other vital non-TNM indicators like gender, age, marital status, serum carbohydrate antigen 19–9 (CA19–9) and tumor differentiation have already been found to associate with PC patient survival [8–10]. In addition, the lymph node ratio (LNR) demonstrated an impact on prognosis [11], and could serve as a active predictor for survival [12, 13]. Therefore, a more precise predicting system is needed to establish to assist clinicians in making individual survival prediction.

Currently, nomograms have been developed and proposed as a novel, alternative tool for prognostic evaluation of many cancers [14–16], which can incorporate important demographic and clinicopathologic characteristics to estimate the individual survival rate for cancer patients. Since PC rarely occurs before the age of 40, a nomogram for PC patients 40 years of age or older undergoing surgical resection derived from population-based data, to our knowledge, has not ever been reported. We aim to formulate a prognostic nomogram with the data from Surveillance, Epidemiology and End Results (SEER) of the US National Cancer Institute (NCI) to better predict individualized prognosis in surgically resected PC patients who are age 40 or older.

**Methods**

**Patient population**

Data of this study were retrieved from the SEER program, which covered up to 97% of incidence of cancer and encompassed 28% of the US population [17], and accessed by SEER*Stat software v. 8.3.5. Inclusion criteria indicated below: 1) Patients were diagnosed with PC as the first and sole carcinoma diagnosis and diagnosing age were ≥40 years old. 2) Those with a confirmed pathological diagnosis from 2010 to 2015 and undergoing surgical resection.3) Site of pancreatic neoplasm (primary site-labeled) was limited to the site code of C25.0, C25.1 and C25.2 from the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). 4) Active following-up with clear data and known outcome. Exclusion criteria were as follows: 1) Patients with second primary carcinoma. 2) Those diagnosed with AJCC TNM stage III or IV who were thought to lose indication for surgery. 3) Those with unknown data about follow-up time, survival information or other characteristics. The enrolled subjects were allocated into a training cohort to develop a nomogram and an internal validation cohort randomly by 2 to 1 ratio.

**Study variables**

The following variables of each patient were gathered: age, gender, carcinoma location, carcinoma grade, carcinoma size, AJCC TNM stage, regional lymph node examined, regional lymph node positive, lymph nodes surgery scope, and survival information. Regional lymph node positive was divided by regional lymph node examined to calculate the LNR value. The primary endpoint was OS with the definition of the duration from the diagnosing date until death due to any cause or last follow-up. The stage of carcinoma was identified by the TNM staging system of AJCC (7th edition). Patients in this study were limited to between 2010 and 2015 in consideration of this staging system having been accessible since 2010.

**Statistical analysis**

All statistical tests were conducted using R project v. 3.5.2(The R Foundation for Statistical Computing, Vienna, Austria. [http://www.r-project.org](http://www.r-project.org)) and SAS v. 9.2 (SAS Institute Inc., USA). Categorical data were presented as frequency and percentage and tested with Chi-square test. Continuous data were expressed as the median and range and compared by Mann-Whitney U test. The optimal value of cutoff for LNR was decided using the analysis of time-dependent receiver operating characteristic (ROC) curve. Cox proportional hazards regression model was adopted to conduct the univariate and multivariate analysis, and we calculated the hazard ratio (HR) together with corresponding 95% confidence interval (CI). The OS were estimated by the Kaplan-Meier method and the test of log-rank was applied to analyze different survival curves. All analysis in this study was performed two-sided at the 5% significance level.

The rms package within R was applied to construct a nomogram on the basis of independent determinants identified in the multivariate Cox regression. The nomogram performance was judged using concordance index (C-index) and assessed by calibration curves as previously described [18]. The C-index value fluctuated from 0.5 to 1.0 with 0.5 representing random opportunity and 1.0 denoting a completely exact discrimination. The calibration curves from study cohort (bootstrap with 300 resamples) were applied to compare the concordance between the observed OS and the predicted OS probability.

**Results**

**Characteristics of patients**

In total, 6341 eligible patients over 40 years old with surgically resected PC from 2010 to 2015 were finally enrolled as the primary cohort, in which a training cohort and an internal validation cohort had 4242 patients and 2099 ones, respectively. The demographic and clinicopathological characteristics of patients were listed in Table 1. There was no statistically significant difference with respect to all the
demographic and clinicopathological characteristics between training set and validation set. The median diagnosing age was 65 years old (range: 40–85 years old) in the whole patient cohort and age difference was not observed between training set and validation set. Totally, 3260 (51.4%) were male, and the most common carcinoma location was pancreatic head (4750, 74.9%). The most common carcinoma grade was moderately differentiated (2866, 45.2%), then was poorly differentiated (2028, 32.0%). The majority of patients (5268, 83.1%) were classified as TNM stage II, followed by stage I (1073, 16.9%). Patients with 4 or more regional lymph nodes removed accounted for 5925 (93.4%). The primary cohort comprised 3195 (50.4%) patients with carcinoma size of 2–4 cm, 1914 (30.2%) patients and 1232 (19.4%) patients with ≥4 cm and ≤2 cm, respectively. LNR was associated to the optimal Youde index for predicting OS with 0.1732 being the cutoff value. The low-risk cohort (LNR ≤0.1732) consisted of 4348 (68.6%) patients.

### Table 1 Demographical and clinicopathological characteristics of patients over 40 years old with surgically resected PC

| Variable                          | Variable level | Training Set (n = 4242) | Validation Set (n = 2099) | p-value |
|-----------------------------------|----------------|-------------------------|----------------------------|---------|
| Age (years)                       | < 60           | 1849 (29.0)             | 618 (29.4)                 | 0.727   |
|                                  | ≥60            | 4492 (71.0)             | 1481 (70.6)                |         |
| Gender                            | Male           | 3260 (51.8)             | 1064 (50.7)                | 0.419   |
|                                  | Female         | 3081 (48.2)             | 1035 (49.3)                |         |
| Tumor Location in pancreas       | Head           | 4750 (74.8)             | 1576 (75.1)                | 0.778   |
|                                  | Body           | 605 (9.4)               | 205 (9.8)                  |         |
|                                  | Tail           | 986 (15.8)              | 318 (15.1)                 |         |
| Grade                             | Well differentiated | 1350 (29.0)              | 422 (20.1)                | 0.433   |
|                                  | Moderately differentiated | 2866 (44.7)                  | 968 (46.1)               |         |
|                                  | Poorly differentiated | 2028 (31.9)               | 676 (32.2)               |         |
|                                  | Undifferentiated | 97 (1.5)                | 33 (1.6)                   |         |
| AJCC TNM stage                    | I              | 1073 (16.8)             | 360 (17.2)                 | 0.732   |
|                                  | II             | 5268 (83.2)             | 1739 (82.8)                |         |
| Regional lymph nodes surgery      | None           | 42 (0.7)                | 11 (0.5)                   | 0.332   |
|                                  | 1~3            | 374 (5.7)               | 134 (6.4)                  |         |
|                                  | ≥4             | 5925 (93.6)             | 1954 (93.1)                |         |
| Tumor size (cm)                   | ≤2             | 1232 (20.1)             | 378 (18.0)                 | 0.128   |
|                                  | (2~4)          | 3195 (50.0)             | 1072 (51.1)                |         |
|                                  | ≥4             | 1914 (32.9)             | 649 (30.9)                 |         |
| LNR                               | ≤0.1732        | 4348 (69.0)             | 1422 (67.7)                | 0.321   |
|                                  | >0.1732        | 1993 (31.0)             | 677 (32.3)                 |         |

**Abbreviations:** PC: pancreatic carcinoma, AJCC: American Joint Committee on Cancer, TNM: Tumor-Node-Metastasis, LNR: lymph node ratio

Univariate and multivariate analysis of determinants of OS

In total, the median follow-up time and median OS was 31 months (range: 1–71) and 25 months (95% CI: 23.95–26.05), respectively. The one-, two-, three-year rates of OS were 73.7, 50.8 and 37.7%, respectively. Totally, 3103/6341 (48.9%) patients died, in which 2742 cancer-specific deaths and 361 non-cancer-specific deaths were observed, respectively. With regard to non-cancer-specific death, the top three most common causes were heart disease (69, 19.1%), septicemia (24, 6.7%) and cerebrovascular disease (18, 5.0%). As univariate test for training cohort showed, age, carcinoma location in pancreas, carcinoma grade, TNM stage, carcinoma size and LNR observed statistically significant associations with OS (P < 0.01), while gender and regional lymph nodes surgery did not meet the prespecified threshold for statistical significance with OS (P > 0.05) (Table 2).

For multivariate Cox regression model, a backward stepwise procedure was performed after selecting all the variables identified by the univariate model as potentially prognostic determinants. Additionally, in view of TNM stage probably being relevant to tumor size and the presence of lymph node metastasis, the possible interaction between TNM stage and tumor size, together with interaction between TNM stage and LNR, were also incorporated into the multivariate model. Multivariate analysis demonstrated that 6 determinants involving age, carcinoma location in pancreas, carcinoma grade,
stage of TNM, carcinoma size and LNR remained as independent survival predictors associated with OS (Table 2). None of interactions were found to be statistically significant in their effects on overall survival. Patients with elder age (HR = 1.328, 95% CI: 1.198–1.471), advanced grade (HR = 2.616 for moderately differentiated, 95% CI: 2.224–3.078; HR = 3.584 for poorly differentiated, 95% CI: 3.034–4.233; HR = 3.385 for undifferentiated, 95% CI: 2.371–4.832), advanced stage of TNM (HR = 1.855 for II stage, 95% CI: 1.542–2.231), enlarged carcinoma (HR = 1.303 for 2–4 cm, 95% CI: 1.136–1.494; HR = 1.512 for ≥4 cm, 95% CI: 1.307–1.749) and LNR larger than 0.1732 (HR = 1.522, 95% CI: 1.388–1.669) suffered from more inferior survival. While patients with carcinoma location in the pancreatic body (HR = 0.875, 95% CI: 0.737–1.038) and carcinoma location in the pancreatic tail (HR = 0.737, 95% CI: 0.634–0.857) were more likely to experience better survival compared with those whose primary tumors were located in pancreatic head. Beyond that, survival curves of Kaplan-Meier demonstrated the OS differences with respect to stratification by these factors were all statistically significant (Fig. 1).

### Constructing and validating nomogram for OS

All of prognostic determinants identified from training set were brought into the construction of the nomogram. Figure 2 could illustrate a nomogram from training cohort which was constructed for the one-, two-, and three-year probabilities of OS. An individual patient’s survival probability may be simply obtained by summing the point of each factor on the points scale to get the total point score, then, the total score is matched vertically downward to the scale of survival to determine the probability. Took 2 stage II PC patients for example (Table 3): the first case with 55-years old was diagnosed with a poorly differentiated tumor of 4 cm in pancreatic head, and the second case who was 65-years old was diagnosed with a moderately differentiated tumor of 4 cm in pancreatic tail. Meanwhile, both of them suffered from a LNR > 0.1732. Using nomogram, those 2 cases had the total points of 20 and 16 respectively, and achieved one-year OS probability of 55 and 72%, respectively. The nomogram showed a well discriminatory precision with the C-index being 0.680 (95% CI: 0.667–0.693). Calibration curves showed an excellent unanimity between the actually observed and nomogram-predicted

### Table 2 Univariate and multivariate analysis of factors associated with OS of patients in the training cohort

| Variable                     | Variable level | Univariate analysis |                 | Multivariate analysis |                 |
|------------------------------|----------------|---------------------|-----------------|-----------------------|-----------------|
|                              |                | HR                  | 95% CI          | p-value               | HR              | 95% CI          | p-value               |
| Age                          | < 60 Reference | 1.517               | 1.370–1.680     | < 0.001               | 1.328           | 1.198–1.471     | < 0.001               |
|                              | ≥60 Reference  | 1.968               | 0.888–1.056     | 0.470                 |                 |                 |                      |
| Gender                       | Male Reference | 0.607               | 0.513–0.719     | < 0.001               | 0.875           | 0.737–1.038     | 0.124                 |
|                              | Female Reference | 0.507               | 0.438–0.588     | < 0.001               | 0.737           | 0.634–0.857     | < 0.001               |
| Tumor Location in pancreas   | Head Reference | 3.495               | 2.983–4.094     | < 0.001               | 2.616           | 2.224–3.078     | < 0.001               |
| Grade                        | Well Reference | 5.210               | 4.437–6.118     | < 0.001               | 3.584           | 3.034–4.233     | < 0.001               |
|                              | Moderately     | 4.274               | 3.001–6.086     | < 0.001               | 3.385           | 2.371–4.832     | < 0.001               |
|                              | Poorly         |                     |                 |                       |                 |                 |                      |
| AJCC TNM stage               | I Reference    | 3.661               | 3.081–4.351     | < 0.001               | 1.855           | 1.542–2.231     | < 0.001               |
|                              | II Reference    | 1.960               | 1.715–2.240     | < 0.001               | 1.303           | 1.136–1.494     | < 0.001               |
| Regional lymph nodes surgery | None Reference | 2.200               | 1.911–2.533     | < 0.001               | 1.512           | 1.307–1.749     | < 0.001               |
| Tumor size (cm)              | ≤2 Reference   | 1.991               | 1.821–2.176     | < 0.001               | 1.522           | 1.388–1.669     | < 0.001               |
|                              | (2–4) Reference | 2.000               | 1.911–2.533     | < 0.001               |                 |                 |                      |
|                              | ≥4             | 1.991               | 1.821–2.176     | < 0.001               |                 |                 |                      |
| LNR                          | ≤0.1732 Reference | 1.477               | 0.600–3.638     | 0.396                 |                 |                 |                      |
|                              | > 0.1732       | 2.198               | 0.914–5.286     | 0.079                 |                 |                 |                      |

**Abbreviations:** OS overall survival, AJCC American Joint Committee on Cancer, TNM Tumor-Node-Metastasis, LNR lymph node
survival for one-, two-, and three-year OS in two sets (Fig. 3).

Survival analysis by risk stratification on the basis of nomogram
Patients in two sets were categorized into low, middle, and high risk cohorts by the total points derived from the nomogram. Those subjects with total points of greater than or equal to 20, 10–19, and less than 10 were identified as the high, middle, and low risk group, respectively. The survival curves of Kaplan-Meier according to risk stratification were demonstrated in Fig. 4. Compared with patients in the high risk group, patients in the rest of two risk groups showed more significantly superior OS rates not only in training set but also in validation set.

Discussion
Several previously reported nomograms for PC patients were based on either limited variables and comparatively small sample size, or no limitation of age, or being irrespective of surgery status [19–21]. Therefore, developing and validating a nomogram for PC with better applicability is still needful. In this study, 6341 patients greater than 40 years old with surgically resected PC were enrolled from the SEER dataset and analyzed to build the OS-predicting nomogram. Six independent prognostic determinants involving age, carcinoma location in pancreas, size of carcinoma, grade, stage of TNM together with LNR were identified through the univariate and multivariate Cox proportional hazard regression. A nomogram based on these factors was constructed and manifested favorable discrimination and
calibration, which meant it might act as a quantitative model to appraise individual OS rate of PC patients.

It appears that age has been a vital prognostic determinant. Within our study which included the patients older than 40 years old, multivariate analysis signified that elder age had a straightforward impact on OS. Further stratified survival analysis manifested patients older than 60 years old had a more inferior survival in comparison with patients with age fallen between 40 and 60 years old. This result resembled other studies which reflected that increasing age might contribute to mortality of patients [20, 21]. Approximately 80 % of all PC occur in pancreatic head, and prognosis of this type of carcinoma continues to be inferior even experiencing pancreaticoduodenectomy which has ten to twenty months of median OS [22]. According to our analysis of Cox regression and log-rank test, patients with carcinoma location in pancreatic head were more likely to experience poorer survival, which was in accordance with the conclusion of Song’s study [20]. Grade of carcinoma demonstrates the biological behavior of neoplasm, which is highlighted for its significant impact on prognosis. It has been indicated that carcinoma differentiation is an independent determinant for predicting OS in similar

Table 3 Comparison of two AJCC TNM stage II PC patients according to variables in Nomogram and 1-year OS

| Variable                      | Patient 1 | Points | 1-year OS | Value | Points | 1-year OS |
|-------------------------------|-----------|--------|-----------|-------|--------|-----------|
| Age                           | 55        | 0      | 65        | 2     |
| Tumor Location in pancreas    | Head      | 2.5    | Tail      | 0     |
| Grade                         | Poorly    | 6.75   | Moderately| 3.25  |
| AJCC TNM stage                | II        | 5      | II        | 5     |
| Tumor size (cm)               | 4         | 2.75   | 4         | 2.75  |
| LNR                           | > 0.1732  | 3      | > 0.1732  | 3     |
| Total Points                   | 20        | 55%    | 16        | 72%   |

Abbreviations: OS overall survival, AJCC American Joint Committee on Cancer, TNM Tumor-Node-Metastasis, LNR lymph node ratio.
researches [10, 22], and our multivariate analysis also showed poorer survival when carcinoma grade shifted to poor differentiation from well differentiation. Based on present nomogram, patients who had different carcinoma grades were given disparate scores and could get diverse survival probability, even though they were sorted into the same stage of TNM. This result clearly exhibited the difference between prognosis derived from traditional TNM staging system and those by nomogram. Considering the above-mentioned example, the two stage II PC patients with different age, pancreatic tumor location and grade suffered from different 1-year OS probability using nomogram. However, according to TNM staging system, both of them were identified as stage II, which indicated the same consequence. Superiority of nomogram in predicting survival compared with TNM staging system could be explained in part. As indicated in this study, TNM stage and tumor size were also involved in the formulation of nomogram, which were in accordance with past studies that signified

![Fig. 3 Calibration plots of nomogram for 1-, 2- and 3-year OS prediction of the training set (a, b, c) and validation set (d, e, f). X-axis represents the nomogram-predicted OS probability and Y-axis represents the actually observed OS probability. The diagonal line indicates the perfect nomogram reference. Dots with bars represent nomogram-predicted probabilities together with 95% confidence interval.](image)

![Fig. 4 Kaplan-Meier OS curves according to the risk levels of nomogram-predicted survival probabilities: (a) Training set, (b) Validation set](image)
the independent impact of the two indicators on OS predicting [20, 23]. Patients with advanced TNM stage and enlarged tumor suffered from higher mortality and poorer survival rate as demonstrated by multivariate Cox regression analysis. As far as we know, LNR value integrates information with respect to positive lymph nodes and total examined lymph nodes. Several studies had shown that increased LNR indicated the potential trend of progression or metastasis and revealed notoriously poorer prognosis [13, 24, 25]. By treating LNR, a continuous variable, as binary categorical variable with the cutoff value of 0.1732 at present study, patients could be easily divided into groups with different risks. Our nomogram allowed a simple and visually friendly means for survival prediction. We found that high LNR value exhibited to be a poorer prognostic indicator for OS, which was similar to the result of significant relationship between low distant metastasis-free survival and elevated LNR level (greater than 0.15) derived from MD Anderson Cancer Center [26]. As with previous study [21], we did not identify the amount of regional lymph nodes surgery as an OS determinant in patients with PC. It can be conjectured LNR value is an excellent indicator for prediction of survival outcome in comparison to the number of regional lymph nodes surgery. AJCC recommends 12 harvested lymph nodes, at a minimum, is sufficient for precisely classifying carcinoma staging as inadequate lymph nodes may result in understaging the N category in PC [27].

At present study, all indicators embodied in the nomogram were significant determinants of OS prediction among patients over 40 years old with surgically resected PC. Our nomogram showed good discrimination with C-index being 0.680. The calibration curve of both training set and internal validation set indicated goodness of fit in predicting survival since the OS at one-, two-, and three-years predicted by nomogram were highly proximate with actual ones, respectively. Furthermore, survival curves stratified by nomogram-predicted survival risk probabilities demonstrated the statistically significant difference both in training cohort and validation one. Our nomogram which was constructed based on the large population of SEER database could embody more generalized applicability. Meanwhile, the nomogram incorporating variables that govern carcinoma prognosis can emerge as a simpler, more sophisticated tool to estimate individual survival risk, and may assist physicians in more accurate prognostic predicting and decision making concerning individual treatment.

Several limitations existed in our study. Firstly, patients were randomly allocated into training cohort for developing nomogram and internal validation cohort for assessing accuracy of nomogram. Though nomogram of present study exhibited perfect performance in OS predicting, validation using other external data is still required to undergo rigorous scrutiny and further evaluate predictive accuracy. Next, some other variables related to prognosis such as CA19–9 [28], the most extensively adopted serum indicator in PC prognosis, and vascular invasion [29] were unaccessible from SEER database. Study covering these variables will be the future research direction. Moreover, this study was based on retrospective data, the large-scaled and prospective study is still needed to eliminate the bias and validate the accuracy of nomogram. Only in this way can nomogram enable perfect prognostication for patients.

Conclusions
We analyzed the clinicopathological factors determining OS of patients over 40 years old with surgically resected PC using a population-based SEER database. Furthermore, nomogram for predicting one-, two-, and three-years OS was developed. Our nomogram demonstrated good performance and can be considered as a novel assessing tool of individual survival.

Abbreviations
AJCC: American Joint Commission on Cancer; CA19–9: Carbohydrate antigen 19–9; CI: Confidence interval; HR: Hazard ratio; ICD-O-3: International Classification of Diseases for Oncology, 3rd Edition; LNR: Lymph node ratio; NCI: National Cancer Institute; OS: Overall survival; PC: Pancreatic carcinoma; ROC: Receiver operating characteristic; SEER: Surveillance, Epidemiology, and End Results; TNM: Tumor-Node-Metastasis

Acknowledgments
The SEER program was appreciated for providing free accessible to the database.

Authors’ contributions
JL designed the study. JL and LS L accessed databases and gathered all variables. JL and LS L assumed responsibility for completeness and accuracy of data analysis and interpretation. The manuscript was written by JL. All authors have read and approved the final manuscript.

Funding
The present study was funded by the grant from the project of clinical management of Shanghai Shenkang hospital development center (SHDC12018629). The funder had no role in study design, data collection and analysis, decision to publish or preparation of manuscript.

Availability of data and materials
We obtained consent to acquire the database with SEER ID: 10930-Nov2017. The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Approval for institutional review board together with written informed consent were waived for this study as SEER database is open accessible and all identity data of subjects are undistinguishable.

Consent for publication
Not applicable.

Competing interests
The authors declared that they have no competing interests.
References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(14):3913–21.
3. Pu N, Lv Y, Zhao G, Lee W, Nueniati A, Wang D, Xu X, Kuang T, Wu W, Lou W. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Future Oncol. 2018; 14(2):165–75.
4. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American joint commission on cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: a glandular ductal surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol. 2017;24(7):2023–30.
5. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet.2016; 388(10039):73–85.
6. Miao DL, Song W, Qian J, Zhi GP, Wu Q, Lv CG, Chen L. Development and validation of a nomogram for predicting overall survival in pancreatic neuroendocrine tumors. Transl Oncol. 2018;11(5):1097–103.
7. Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on Cancer and European neuroendocrine tumor society systems. J Clin Oncol. 2017;35(3):274–80.
8. Wang XD, Qian J, Bai DS, Li ZN, Jiang GQ, Yao J. Marital status independently predicts pancreatic cancer survival in patients treated with surgical resection: an analysis of the SEER database. Oncotarget. 2016;7(17):24880–7.
9. Ji F, Fu SJ, Guo ZY, Pang H, Ju WQ, Wang DP, Hu YP, He XS. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2016;95(27):e4065.
10. Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, Hines OJ, Donahue TR, Reber HA, Tomlinson JS. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNM staging system. Ann Surg Oncol. 2013;20(12):3422–9.
11. ac B, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004; 70(3):235–40.
12. Tol JA, Brosens LA, van Dieren S, van Gulik TM, Busch OR, Besselink MG, Donahue TR, Reber HA, Tomlinson JS. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNM staging system. Ann Surg Oncol. 2013;20(12):3422–9.
13. Zhan HK, Xu JW, Wang L, Zhang GY, Hu SY. Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer. World J Surg Oncol. 2015;13:105.
14. Zhang ZY, Luo G, Sun Z, Basset S, Ge HY. Nomograms to predict survival after colorectal cancer resection without preoperative therapy. BMC Cancer. 2016;16(1):658.
15. Liu J, Geng Q, Liu Z, Chen S, Guo J, Kong P, Chen Y, Li W, Zhou Z, Sun X, et al. Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry. Oncotarget. 2016;7(24):35853–64.
16. Li Y, Ju L, Xie Y, Gao W, Wang Z, Li Q, Ma C, Zhao Z, Ren Y, Sun M. Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study. Oncotarget. 2017;8(15):24469–82.
17. Wu Q, Wang WJ, Huang YQ, Fang SY, Guan YJ. Nomograms for estimating survival in patients with liver-only colorectal metastases: a retrospective study. Int J Surg. 2018;60:1–8.
18. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–23.
19. Vernerey D, Huguet F, Venot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Gillemelus B, Anru P, Moore MJ, Andre T, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer. 2016;115(3):281–9.
20. Song W, Mao DL, Chen L. Nomogram for predicting survival in patients with pancreatic cancer. Oncol Targets Ther. 2018;11:539–45.
21. Pu N, Li J, Xu Y, Lee W, Fang Y, Han X, Zhao G, Zhang L, Nueniati A, Yin H, et al. Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis. Cancer Manag Res. 2018;10:227–38.
22. He C, Zhang Y, Cai Z, Lin X, Li S. Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: a competing risk nomogram analysis. J Cancer. 2018;9(7):3156–67.
23. White RR, Kattan MW, Haney JC, Claym BM, Pappas TN, Tyler DS, Brennan MF. Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. Ann Surg Oncol. 2006;13(11):1485–92.
24. Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2014;18(11):2359–35.
25. Smith BJ, Mezhr IJ. An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic cancer patients. J Am Med Inform Assoc. 2014;21(2):e203–11.
26. Roland CL, Katz MH, Gonzalez GM, Pisters PW, Vauthey JN, Wolf RA, Crane CH, Lee J, Fleming JB. A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma. J Gastrointest Surg. 2012;16(11):2056–63.
27. Siddell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, Choti MA, Pavlik TM. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large population-based analysis. Ann Surg Oncol. 2008;15(1):165–74.
28. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Washaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic carcinoma. J Clin Oncol. 2006;24(18):2897–902.
29. Shen YN, Guo CX, Pan Y, Chen YW, Tang TY, Li YW, Lu JH, Jin Q, Qin YX, Yao WY, et al. Preoperative prediction of peripancreatic vein invasion by pancreatic head cancer. Cancer Imaging. 2018;18(1):49.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.